Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.
2.

Where are we with postmenopausal hormone therapy in 2005?

Lam PM, Chung TK, Haines C.

Gynecol Endocrinol. 2005 Nov;21(5):248-56. Review.

PMID:
16373243
3.

Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.

Col NF, Pauker SG, Goldberg RJ, Eckman MH, Orr RK, Ross EM, Wong JB.

Arch Intern Med. 1999 Jul 12;159(13):1458-66.

PMID:
10399897
4.

HRT misuse and the osteoporosis epidemic.

Gambacciani M.

Climacteric. 2012 Feb;15(1):10-1. doi: 10.3109/13697137.2011.639527. Epub 2011 Dec 1. Review.

PMID:
22132704
5.

Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy.

Tosteson AN, Rosenthal DI, Melton LJ 3rd, Weinstein MC.

Ann Intern Med. 1990 Oct 15;113(8):594-603.

PMID:
2119161
6.

A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects.

O'Connell D, Robertson J, Henry D, Gillespie W.

Climacteric. 1998 Jun;1(2):112-23. Review.

PMID:
11907914
7.
8.

Hormone therapy to prevent hip fractures in elderly.

Brzezny AL.

Am Fam Physician. 2003 Oct 15;68(8):1489; author reply 1489-90. No abstract available.

9.

Socio-demographic characteristics of postmenopausal estrogen users.

Strinić T, Buković D, Karelović D, Despot A, Buković N, Giudici E, Silovski H.

Coll Antropol. 2002 Jun;26(1):245-9.

PMID:
12137306
10.

Estrogen therapy for postmenopausal osteoporosis.

Fitzpatrick LA.

Arq Bras Endocrinol Metabol. 2006 Aug;50(4):705-19. Review.

11.

Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women.

Bakhireva LN, Shainline MR, Carter S, Robinson S, Beaton SJ, Nawarskas JJ, Gunter MJ.

Pharmacotherapy. 2010 Sep;30(9):879-87. doi: 10.1592/phco.30.9.879.

PMID:
20795843
12.

Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort.

Engel P, Fabre A, Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F.

Am J Epidemiol. 2011 Jul 1;174(1):12-21. doi: 10.1093/aje/kwr044. Epub 2011 May 9.

PMID:
21555715
13.

Prevention of hip fractures: drug therapy.

Lips P.

Bone. 1996 Mar;18(3 Suppl):159S-163S. Review.

PMID:
8777082
14.

Late prevention of hip fractures with hormone replacement therapy.

Stevenson JC.

Osteoporos Int. 1996;6 Suppl 3:64-7. Review. No abstract available.

PMID:
8931051
15.

Prognostic features of menopausal and postmenopausal applicants for life insurance.

Schiefeling M.

J Insur Med. 1996;28(1):27-34. Review.

PMID:
10172866
16.

Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women.

Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD.

Am J Public Health. 1995 Aug;85(8 Pt 1):1128-32.

17.

Use of low potency estrogens does not reduce the risk of hip fracture.

Michaëlsson K, Baron JA, Farahmand BY, Ljunghall S.

Bone. 2002 Apr;30(4):613-8.

PMID:
11934654
18.

Statement on results of the HERS II trial on hormone replacement therapy.

American College of Obstetricians and Gynecologists..

Ginecol Obstet Mex. 2002 Aug;70:406-8. No abstract available.

PMID:
12448046
19.

Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women.

Beral V, Reeves G, Banks E.

BJOG. 2005 Jun;112(6):692-5. Review. No abstract available.

20.

Hormones and bone health in postmenopausal women.

Lindsay R.

Endocrine. 2004 Aug;24(3):223-30. Review.

PMID:
15542889

Supplemental Content

Support Center